News

NANBIOSIS Unit 26 to Present NMR and Metabolomics Capabilities at Universitat de València

NANBIOSIS Unit 26 will present its NMR and metabolomics capabilities in a free seminar at Universitat de València on 2 July 2026.

Valencia, July 2026 — On Thursday, 2 July 2026, researchers, students, and healthcare professionals will have the opportunity to learn more about the biomedical applications of nuclear magnetic resonance and metabolomics during the seminar “Biomedical Imaging and Metabolomics Section: Our Experience”.

The event will take place at 13:00 in Seminar Room D, on the main floor of the Faculty of Medicine and Dentistry at the Universitat de València. It is organized by the Biomedical Imaging and Metabolomics Section of the Central Research Unit in Medicine (UCIM).

The seminar will present the equipment available in the section, with special emphasis on recent improvements, updates, and their biomedical applications. In particular, the session will highlight the capabilities associated with NANBIOSIS Unit 26 – NMR: Biomedical Applications II, a key infrastructure for biomedical research based on nuclear magnetic resonance and related analytical techniques.

Attendees will learn more about the following services and technologies, all particularly oriented towards their biomedial application.

With regard to the Imaging Platform:

• Magnetic Resonance Imaging (MRI-3T)
• PET/CT (Positron Emission Tomography / Computed Tomography)
• IVIS (In Vivo Imaging System)
• Irradiator

With regard to the Metabolomic Platform:

• Chromatographic techniques
• 600 MHz NMR spectroscopy
• Hematology and biochemistry analyses

These tools support research in metabolism, biomarker discovery, and the study of disease-related biological processes, helping to advance biomedical research and translational applications.

The seminar will be delivered by Carlos Ezquer Garin and Mustafa Ezzeddin Ayoub (Musta), Senior Technicians of the Biomedical Imaging and Metabolomics Section at UCIM, Faculty of Medicine and Dentistry, Universitat de València.

Those interested in attending are invited to confirm their participation by contacting musez[at]uv.es. Alternativelly, you can also reach out through our contact form and we will forward your application directly to the Unit.

Through initiatives such as this seminar, NANBIOSIS continues to promote access to advanced research infrastructure and strengthen collaboration in the biomedical sciences.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

New rapid blood test prototype could help detect pancreatic cancer in minutes

Researchers develop a rapid blood test prototype for pancreatic cancer, highlighting the potential of antibody-based diagnostics for early detection.

Barcelona, June 2026 — A multidisciplinary team of researchers in Barcelona, including notable names from CIBER and NANBIOSIS, has developed a prototype diagnostic test capable of detecting pancreatic cancer in minutes from a blood sample. The study, published in Talanta, demonstrates the potential of a low-cost, easy-to-use device for identifying a key biomarker associated with pancreatic ductal adenocarcinoma, the most common and deadliest form of pancreatic cancer.

The work was carried out by scientists from the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute for Biomedical Research of Barcelona (IIBB-CSIC), and the Hospital del Mar Research Institute (HMRIB). The prototype was evaluated using plasma samples from 20 patients with pancreatic cancer and 20 healthy individuals.

The test detects soluble AXL (sAXL), a protein that is abnormally elevated in more than 70% of pancreatic tumors. Using a quantitative lateral flow immunoassay—similar to commercial rapid tests—the device provided clear differentiation between samples from patients and healthy controls in just a few minutes.

“This is the first application of a quantitative lateral flow immunoassay for detecting sAXL in plasma,” explains Juan Pablo Salvador, researcher at IQAC-CSIC and corresponding author of the study. The measurements were validated against ELISA, a standard laboratory technique, confirming the diagnostic relevance of the new approach.

Early diagnosis remains one of the major challenges in pancreatic cancer, as more than 85% of patients are diagnosed at stages when surgery—the only curative treatment currently available—is no longer possible. Fast, minimally invasive, and affordable diagnostic tools could therefore have a significant impact on patient survival.

The study also highlights the importance of interdisciplinary collaboration and translational research. Supported by the CSIC BBQ-CSIC 2022 seed funding program, the project involved experts in nanobiotechnology, cancer biology, hemostasis, and clinical oncology, with additional support from the Instituto de Salud Carlos III, the Spanish Ministry of Science, Innovation and Universities, and the Spanish Pancreatic Cancer Patients Association (ACANPAN).

NANBIOSIS Unit 2 contributes expertise in antibody technologies

The development of the immunoassay benefited from the expertise and facilities available at NANBIOSIS Unit 2 (Custom Antibody Service, CAbS), located at IQAC-CSIC and directed by Prof. Pilar Marco. Unit 2 specializes in the development and production of monoclonal and polyclonal antibodies and the performance of immunoassays under an ISO 9001-certified quality management system.

Its capabilities in antibody production, purification, and assay development support innovative diagnostic technologies with translational potential, contributing to advances in precision medicine and point-of-care diagnostics.

Reference

Vázquez-Bellón, N., Rodríguez-Núñez, M., Martínez-Bosch, N., Barranco, L. E., Visa, L., García de Frutos, P., Marco, M. P., Navarro, P., & Salvador, J. P. Lateral flow immunoassay detection of soluble AXL for pancreatic ductal adenocarcinoma diagnosis. Talanta (2026). DOI: 10.1016/j.talanta.2026.129973.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS Unit 6 Research Featured During ICMAB Scientific Advisory Board Visit

NANBIOSIS Unit 6 contributed to advanced nanomedicine research showcased at the ICMAB Scientific Advisory Board visit.

Barcelona, May 2026 — Researchers from Institut de Ciència de Materials de Barcelona (ICMAB-CSIC) recently presented a poster highlighting innovative developments in fluorescent nanovesicles, dendrimers, and organic nanoparticles for sensing and bioimaging during the visit of the institute’s Scientific Advisory Board (SAB). The visit formed part of the evaluation activities linked to the Severo Ochoa excellence accreditation awarded to ICMAB.

The poster showcased multidisciplinary research focused on the development of advanced nanomaterials for biomedical imaging, biosensing, and diagnostic applications. Among the technologies presented were highly stable fluorescent quatsomes for bioimaging and nucleic acid sensing, ultrabright nanoparticles for deep-tissue imaging, and multifunctional dendrimers combining fluorescent and magnetic resonance imaging (MRI) capabilities.

Part of this research was carried out with the support of NANBIOSIS Unit 6, whose contribution was acknowledged in the poster. The Scientific Director of NANBIOSIS, Ramón Martínez Máñez, also participated in the Scientific Advisory Board committee involved in the visit.

The work reflects the growing impact of nanotechnology and advanced biomaterials in the development of next-generation biomedical imaging and sensing tools. These innovative platforms could contribute to improved diagnostics, real-time monitoring, and future personalized medicine applications.

The poster included contributions from researchers affiliated with CIBER-BBN and ICMAB-CSIC, with several of the presented studies recently published in leading scientific journals in materials science and nanomedicine.

NANBIOSIS Unit 6: Advanced materials for health

The poster highlights the mission of NANBIOSIS Unit 6, located at ICMAB-CSIC and coordinated by Prof. Nora Ventosa. This Unit specializes in the development, characterisation, and scale-up of molecular biomaterials with applications in biomedicine.

Equipped with state-of-the-art facilities and operating under ISO 9001 quality standards, Unit 6 offers advanced technologies such as the DELOS-SUSP method, a compressed-fluid-based process for producing highly controlled micro- and nanostructured materials. Its unique capability to scale processes from laboratory to industrial levels supports both research and technology transfer.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Platinum Nanoparticles Boost Radiotherapy Effectiveness Against Cancer

Researchers from INMA and NANBIOSIS have developed ultrasmall platinum nanoparticles that significantly boost radiotherapy effectiveness against cancer.

Zaragoza, May 2026 — Researchers from the Aragon Nanoscience and Materials Institute (INMA), together with collaborators from Instituto de Salud Carlos III, Spanish National Cancer Research Centre (CNIO) and the University of Elche, have developed ultrasmall platinum nanoparticles capable of significantly enhancing the effectiveness of radiotherapy in cancer treatment.

The study, published in Advanced Functional Materials, demonstrates that platinum nanoparticles measuring just 2–3 nanometres act through a dual mechanism to attack tumours. On one hand, platinum amplifies the radiation effect, increasing DNA damage in cancer cells. On the other, the nanoparticles locally generate oxygen inside tumours, helping overcome tumour hypoxia — one of the main causes of resistance to radiotherapy.

The research was led by José Ignacio García-Peiró, Miguel Encinas, José Luis Hueso and Jesús Santamaría, all members of CIBER-BBN and Unit 9 of NANBIOSIS.

Experiments carried out in cell and animal models showed a strong reduction in tumour growth while using low radiation doses, without detecting systemic toxicity. The ultrasmall size of the nanoparticles also facilitates their elimination through the urinary system, improving biocompatibility and safety.

Although still at the proof-of-concept stage, this work represents a promising step toward more effective and targeted radiotherapy strategies in cancer treatment.

The full article, Ultrasmall Platinum Nanoparticles for Radiation-Enhanced Cancer Therapy, is available in Advanced Functional Materials.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Open Seminar Today at I3A: Prof. Jaap den Toonder on Microfluidic Technologies for Biomedical Innovation

Join today’s open seminar at I3A on microfluidic technologies for biomedical innovation, featuring Prof. Jaap den Toonder from TU Eindhoven.

Zaragoza, May 2026 — NANBIOSIS invites researchers, students, and professionals to attend today’s open seminar, “Microfluidic Technologies Enabling Novel Biomedical Applications,” presented by Prof. Jaap den Toonder from Eindhoven University of Technology (TU/e).

The seminar will take place today, May 6, at 12:30 PM in the I3A Seminar Room, Floor 2, Block 5, offering attendees the opportunity to explore how microfluidic technologies are advancing biomedical research and healthcare innovation.

Prof. den Toonder is Full Professor and Chair of the Microsystems section at Eindhoven University of Technology since 2013. He holds both his MSc in Applied Mathematics and PhD in Mechanical Engineering (both cum laude) from Delft University of Technology. Before joining TU/e, he worked at Philips Research Laboratories Eindhoven as Principal Scientist and Chief Technologist.

His research focuses on “making things work at small scales” by developing smart materials, innovative technological concepts, and advanced microfabrication methods for microsystems. These technologies support cutting-edge applications in health and wellbeing, particularly in microfluidic chips, organ-on-chip systems, biomedical microdevices, and soft microrobotics.

With more than 180 scientific publications, over 60 patents, and more than 65 invited lectures at international conferences, Prof. den Toonder is a leading figure in the field of microfluidics and microsystems engineering. He also serves as scientific advisor to six spin-off companies originating from his research group.

Among his major achievements, he founded and directs the Microfab/lab, a state-of-the-art TU/e facility dedicated to the fabrication and analysis of microfluidic devices, microsystems, and biological materials. He is also the recipient of two ERC Advanced Grants (2019 and 2025) and has been a Fellow of the Netherlands Academy of Engineering since 2023.

The seminar is organized by TME Lab and is open to all interested attendees.

This event represents an excellent opportunity for the broader scientific community to discover how microfluidic technologies are enabling next-generation biomedical applications, from personalized medicine to advanced disease models.

Event details:

• Speaker: Prof. Jaap den Toonder
• Title: Microfluidic Technologies Enabling Novel Biomedical Applications
• Date: May 6, 2026
• Time: 12:30 PM
• Location: I3A Seminar Room, Floor 2, Block 5
• Organizer: TME Lab
• Admission: Open seminar

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

SPARTA® technology showcased at ICMAB seminar on advanced nanoparticle characterisation

Seminar at ICMAB highlights SPARTA® technology for high-resolution nanoparticle characterization, advancing nanomedicine research and innovation.

Barcelona, April 2026 — Last April 13, 2026, the Institut de Ciència de Materials de Barcelona (ICMAB-CSIC) hosted a cutting-edge seminar on nanoparticle analysis, featuring Dr. Jelle Penders, CEO of SPARTA Biodiscovery. The event brought together researchers and professionals interested in the latest advances in nanomedicine and materials science.

Titled “From Targeting Moieties to Drug Loading: High Resolution Chemical Profiling of Nanoparticles with SPARTA”, the seminar introduced SPARTA® (Single Particle Automated Raman Trapping Analysis), an innovative technology that enables chemical fingerprinting at the single nanoparticle level. This approach represents a significant leap beyond conventional bulk analysis methods, allowing researchers to better understand the complexity and heterogeneity of nanoformulations.

A new standard in nanoparticle characterisation

During the session, Dr. Penders demonstrated how SPARTA® can be applied to a wide range of nanomaterials, including lipid and polymer nanoparticles (LNPs/PNPs) and extracellular vesicles. Through real-world case studies, attendees learned how the technology can:

• Assess the distribution and heterogeneity of targeting moieties on nanoparticle surfaces
• Quantify drug loading efficiency, distinguishing between loaded and unloaded particles
• Provide detailed chemical profiling to confirm the incorporation of key components

These capabilities are increasingly relevant for both academic and industrial applications, where precise characterisation is essential for drug development, quality control, and regulatory compliance.

Bridging research and innovation

SPARTA® has already seen adoption across academia and industry, accelerating development pipelines and enabling more robust decision-making in nanomedicine. The technology originates from research at Imperial College London, where Dr. Penders completed his PhD under the supervision of leading experts in nanomaterials characterisation.

The seminar was hosted by Dr. Elisabet González Mira, researcher in the NANOMOL-BIO group at ICMAB and Scientific Coordinator of NANBIOSIS Unit 6, as well as Principal Investigator of the Nano4Rare project. The event was organized by the ICMAB Seminars and Training Committee and held both onsite and online, expanding its reach to a broader scientific audience.

NANBIOSIS Unit 6: Advanced materials for health

The seminar aligns with the mission of NANBIOSIS Unit 6, located at ICMAB-CSIC and coordinated by Prof. Nora Ventosa. This Unit specializes in the development, characterisation, and scale-up of molecular biomaterials with applications in biomedicine.

Equipped with state-of-the-art facilities and operating under ISO 9001 quality standards, Unit 6 offers advanced technologies such as the DELOS-SUSP method, a compressed-fluid-based process for producing highly controlled micro- and nanostructured materials. Its unique capability to scale processes from laboratory to industrial levels supports both research and technology transfer.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Technical seminar on materials characterization at ICMAB

Free seminar at ICMAB-CSIC on April 14, 2026, showcases advanced particle characterization techniques with hands-on sessions. Limited seats available.

Barcelona, April 2026 — Next tuesday, April 14 2026, the Soft Materials Service (Unit 6) of NANBIOSIS, in collaboration with the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), will host a Technical Seminar on Materials Characterization, offering a unique opportunity to explore cutting-edge techniques in particle analysis and material science.

This free event will bring together experts and industry professionals to present the latest advances in particle size analysis and material characterization. Attendance is free of charge, and participants may request a certificate of attendance.

Please note that capacity is limited.

Exploring advanced particle characterization techniques

The seminar will cover a wide range of analytical methods essential for nanomedicine, biomaterials, and materials science. Attendees will gain insights into key techniques such as laser diffraction, Dynamic Light Scattering (DLS), and Nanoparticle Tracking Analysis (NTA), as well as microscopy-based approaches and stability analysis.

The program includes contributions from Nane Equipamientos, a company specialized in supplying and advising on material characterization equipment.

A hands-on learning experience

The event is structured into two main blocks:

• Morning session (theoretical): Expert-led presentations introducing particle characterization techniques, their applications, and data interpretation.
• Afternoon session (practical): Interactive demonstrations where participants will have the opportunity to use advanced instrumentation, including laser diffraction systems, optical microscopy, DLS, and NTA equipment.

This combination ensures a comprehensive understanding of both the theory and real-world application of these technologies. You can see the detailed agenda here.

Supporting innovation through shared infrastructures

As part of NANBIOSIS, the Soft Materials Unit (U6) continues to foster innovation by providing access to state-of-the-art facilities and expertise in materials characterization. Events like this seminar reinforce its mission to support researchers, companies, and innovators in advancing nanotechnology and biomedical applications.

Registration and contact

The seminar is open to researchers, students, and industry professionals interested in materials characterization. Due to limited seating, early registration is recommended. You can register in the website or using the QR code below.

For more information, participants can contact the organizers via email at info@nane.pro. To know more about this event, you can visit nane’s website.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: